AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.
AbbVie Prices Arthritis Drug at $59,000 a Year
Comment
Show comments
Hide Comments
